Live feed09:00:00·53dPRReleasevia QuantisnowArcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric DermatologyByQuantisnow·Wall Street's wire, on your screen.ARQT· Arcutis Biotherapeutics Inc.Health Care
